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ABSTRACT
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Increasing evidence indicates that mitochondrial-associated redox signaling contributes to the pathophysiology
of heart failure (HF). The mitochondrial-targeted antioxidant, mitoquinone (MitoQ), is capable of modifying
mitochondrial signaling and has shown beneficial effects on HF-dependent mitochondrial dysfunction. However,
the potential therapeutic impact of MitoQ-based mitochondrial therapies for HF in response to pressure overload
is reliant upon demonstration of improved cardiac contractile function and suppression of deleterious cardiac
remodeling. Using a new (patho)physiologically relevant model of pressure overload-induced HF we tested the
hypothesis that MitoQ is capable of ameliorating cardiac contractile dysfunction and suppressing fibrosis. To test
this C57BL/6J mice were subjected to left ventricular (LV) pressure overload by ascending aortic constriction
(AAC) followed by MitoQ treatment (2 µmol) for 7 consecutive days. Doppler echocardiography showed that
AAC caused severe LV dysfunction and hypertrophic remodeling. MitoQ attenuated pressure overload-induced
apoptosis, hypertrophic remodeling, fibrosis and LV dysfunction. Profibrogenic transforming growth factor-β1
(TGF-β1) and NADPH oxidase 4 (NOX4, a major modulator of fibrosis related redox signaling) expression increased markedly after AAC. MitoQ blunted TGF-β1 and NOX4 upregulation and the downstream ACC-dependent fibrotic gene expressions. In addition, MitoQ prevented Nrf2 downregulation and activation of TGF-β1mediated profibrogenic signaling in cardiac fibroblasts (CF). Finally, MitoQ ameliorated the dysregulation of
cardiac remodeling-associated long noncoding RNAs (lncRNAs) in AAC myocardium, phenylephrine-treated
cardiomyocytes, and TGF-β1-treated CF. The present study demonstrates for the first time that MitoQ improves
cardiac hypertrophic remodeling, fibrosis, LV dysfunction and dysregulation of lncRNAs in pressure overload
hearts, by inhibiting the interplay between TGF-β1 and mitochondrial associated redox signaling.

1. Introduction
Heart failure (HF) is a leading cause of mortality and morbidity in
the United States. Regardless of etiology, HF is heralded by some
common molecular, cellular, and biochemical events collectively called
cardiac remodeling that manifest as alterations in size, shape, structure,

and function of the heart [1]. In the case of pressure overload resulting
from an aortic stenosis or systemic arterial hypertension, the heart often
develops an adaptive concentric hypertrophy, characterized by increased left ventricular (LV) wall thickness with little or no change in
chamber size [2]. However, as compensated hypertrophic remodeling
can only temporarily sustain cardiac function, concentric hypertrophy

Nonstandard abbreviations and acronyms: MitoQ, Mitoquinone; ROS, Reactive oxygen species; AAC, Ascending aortic constriction; TGF-β, Transforming growth
factor beta; NOX4, NADPH oxidase 4; SMAD, Mothers against decapentaplegic homolog; HW, Heart weight; LW, Lung weight; TL, Tibia length; LV, Left ventricle;
IVSd, Interventricular septal end diastole; PWTd, Posterior wall thickness, diastole; IVSs, Interventricular septal end systole; PWTs, Posterior wall thickness, systole;
CO, Cardiac output.; FS, Fractional shortening; EF, Ejection fraction; ESD, End-systolic diameter; EDD, End-diastolic diameter; ESV, End-systolic volume; EDV, Enddiastolic volume; SV, Stroke volume; lncRNA, Long noncoding RNA; Nrf2, nuclear factor erythroid 2-derived factor 2; GSR, Glutathione reductase; PGC-1α,
Peroxisome proliferator-activated receptor gamma coactivator 1α
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will gradually progress to eccentric hypertrophy and eventually to
systolic heart failure if the stress is sustained. During the transition from
compensated hypertrophy to decompensated heart failure, severe fibrosis usually occurs concurrently with cardiomyocyte hypertrophy,
cellular apoptosis, and inflammatory cell infiltration [3].
Extensive studies have demonstrated that fibrosis exerts adverse
effects on cardiac structure and function [4], including increased
muscle stiffness, reduced contractility, and abnormal electrical transduction. In pressure overload-induced HF, transforming growth factorβ1 (TGF-β1), a multifunctional cytokine that regulates cellular proliferation, differentiation, and extracellular matrix production, is a key
mediator of fibrosis progression. Binding of TGF-β1 to its membrane
receptors phosphorylates transcription factors SMAD2/3, which activates the canonical (SMAD-dependent) fibrogenic pathway [5,6],
leading to myofibroblast differentiation and fibrosis [7]. In addition,
TGF-β1 can upregulate NADPH oxidase 4 (NOX4) expression and hence
modulate redox signaling pathways [8]. Moreover, redox signaling
mechanisms, potentially involving mitochondrial superoxide and hydrogen peroxide production, have been shown to involve in TGF-β1
activation and signaling [9]. Thus, a vicious positive feedback loop
exists between TGF-β1, NOX4, and redox signaling [10], facilitating
amplification of the profibrogenic effects of TGF-β1. In addition to
promoting fibrosis, redox signaling has been shown to be implicated in
hypertrophic remodeling and increased cellular apoptosis. Increased
levels of reactive oxygen species (ROS) can stimulate signaling cascades
including those involving protein kinase C (PKC), mitogen-activated
protein kinase (MAPK) [11], c-Jun N-terminal kinase (JNK) [12], and
GTP-binding protein Ras [13] - all implicated in hypertrophy and
apoptosis (reviewed in Tsutsui et al. [14]). Thus, dysregulation of redox
signaling appears to be commonly associated with deleterious cardiac
remodeling events [15], suggesting that targeting redox signaling is a
potential therapeutic strategy for HF treatment.
Mitoquinone (MitoQ) is a derivative of Coenzyme Q, in which
Coenzyme Q is linked to a positively charged group TPP+ in which the
cationic charge has been delocalized. Consequently, this lipophilic
conjugated compound can readily cross biological membranes and accumulates in mitochondria at high concentrations [16]. Over the last
decade, MitoQ has been proven to effectively attenuate redox related
pathologies in both in vitro [17] and in vivo [18] studies including
suppression of fibrosis in the liver and kidney [19,20]. With respect to
cardiac hypertrophy and HF, it has been shown that MitoQ attenuates
mitochondrial dysfunction in both volume overload [21] and pressure
overload [22] rat models. A perplexing aspect of these studies is the
lack of effect of MitoQ in reversing or preventing the loss of cardiac
function which occurs in these models. This disconnect raises three
important possibilities that need to be addressed: a) the impairment of
cardiac physiological function in HF is unrelated to mitochondrial activity; b) mitochondria are involved in the pathophysiology of HF but
MitoQ is ineffective; and c) the mitochondrial contribution to the pathophysiology is not directly related to changes in the capacity to
generate ATP but the retrograde signaling that regulates fibrosis. For
mitochondrial therapeutics to be applied in a translational setting these
aspects of the mechanisms need to be resolved and this is the focus of
the current study.
While it is the case that studies in other organs have suggested that
MitoQ is capable of suppressing the signaling that controls the development of fibrosis this has not been investigated in the failing heart.
This is critical since there is a strong link between fibrosis and the
pathophysiology of HF [23]. Accordingly, we tested the key mechanistic hypothesis that MitoQ can improve cardiac remodeling and LV
dysfunction by suppressing the mitochondrial redox signaling that
mediates the TGF-β1-NOX4-ROS vicious cycle, leading to decreased
SMAD-mediated pro-fibrotic transcript regulation.
An important reason for the apparent lack of efficacy of MitoQ in
the TAC rat may be due to limitations of the models used such as lack of
fibrosis and sufficient ejection fraction reduction, the main criteria for

HF classification [22]. In this study, we utilized an ascending aortic
constriction (AAC)-induced pressure overload HF mouse model that
rapidly develops severe fibrosis and profound LV dysfunction. This offers significant advantages over the traditional transverse aortic constriction (TAC) models that may take months to develop HF, if they
develop HF at all. In fact, some laboratories have resorted to a “double
hit” model of aortic constriction and arterial ligation [24]. By using our
AAC model we can produce HF in a timely manner while address
therapies without secondary and longer-term complications from
models that develop failure over a longer timeframe. Our data demonstrate that MitoQ significantly improved LV hypertrophic remodeling and cardiac contractile dysfunction and attenuated development of fibrosis in failing hearts. Consistent with these observations,
both in vivo animal and in vitro cardiac fibroblast experiments reveal
that MitoQ suppressed TGF-β1-induced oxidative stress and upregulation of TGF-β1, NOX4, and the downstream genes involved in the fibrosis network. As a significant extension of these mechanistic studies,
we show data which implicates a role for long noncoding RNAs
(lncRNAs), such as cardiac hypertrophy-associated transcript (Chast), in
HF-dependent fibrosis, supporting the emerging role of these factors as
critical regulators of pathological cardiac remodeling [25]. Preliminary
results of this work have been published in abstract form [26].
2. Methods
All data and materials supporting the findings of this study are
available within the article and in the Online Data Supplement or from
the corresponding authors on reasonable request.
2.1. Animals
Adult C57BL/6J mice were obtained from Jackson laboratories and
housed in an animal facility at the University of Alabama at
Birmingham. This study conforms to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and has been approved by the
Institutional Animal Care and Use Committee at University of Alabama
at Birmingham.
2.2. Ascending aortic constriction (AAC)
Nine-week-old male mice were anesthetized with 2% isoflurane and
placed in the supine position on a heating pad (37 °C). After a horizontal skin incision of ~1 cm in length at the level of the suprasternal
notch, a ~3 mm longitudinal cut was made in the proximal portion of
the sternum. Surgery was then performed as previously described [27],
with the following modifications. Specifically, minimally invasive surgery was performed in which the aorta was accessed via a small incision
of the upper sternum which meant the mice did not require intubation.
Following this entry an ascending aortic constriction (AAC) was performed by placing a titanium ligating clip (Teleflex, Catalog # 005200)
that had been calibrated to 31-gauge needle diameter around the ascending aorta. The sham operation was performed following the same
procedure without clip application. Twenty-four hours after AAC or
sham surgery, 100 μL of water or MitoQ (2 µmol) was administered by
oral gavage every morning at the same time for 7 days. Mouse body
weight and consumption of drinking water were monitored. Tissue was
harvested at the end of treatment for gravimetric and molecular measures.
2.3. Echocardiography
Transthoracic echocardiography were performed on mice to evaluate the peak pressure gradient and cardiac function using a 30 MHz
RMV707B transducer and VisualSonics Vevo770 High-Resolution
System (VisualSonics, Toronto, ON, Canada) as previously described
2
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[28]. In brief, mice were anesthetized with 1.5% inhaled isoflurane
anesthesia (with 100% supplemental oxygen) and placed on a heated,
bench-mounted adjustable rail system. The peak pressure gradient (ΔP)
across the constriction was measured using pulse wave Doppler velocity
(V) (ΔP = 4V2) two days after AAC surgery. One week after AAC and
MitoQ treatment, two-dimensionally directed M mode images were
captured from the long axis views. Left ventricular (LV) end-diastolic
and end-systolic dimensions, and LV end-diastolic posterior wall
thickness, were measured from the M-mode images, and LV fractional
shortening was calculated with VisualSonics V1.3.8 software.

Table 1
List of real-time RT-PCR primers.

2.4. Gravimetric and histological analysis
Mice were sacrificed, and cardiac and lung tissues were collected.
Weights of heart and lung and length of tibia of each mouse were
measured. For histological analysis, LV tissues were fixed with formalin, embedded with paraffin, and sectioned at 5 µm thickness.
Sections were then deparaffinized in CitriSolv and rehydrated through
washes of descending percentage of ethanol.
2.4.1. Wheat germ agglutinin staining
To assess cardiomyocyte cross-sectional area, tissue sections were
stained with Alexa Fluor 488-conjugated wheat germ agglutinin
(1:1000). Slides were imaged with an Olympus FV1000 confocal microscope. Cardiomyocytes with transversely cross-sectioned and revealing thin and intact cell borders were included in size measurement.
Around 60 cardiomyocytes per mouse were measured using ImageJ
software to acquire a proper representation of the tissue.

mRNA

Forward

Reserve

Nppa
Nppb
Chast
Malat-1
Mhrt
Agt
Pdgf
Tgf-β1
Edn1
Nox4
Ctgf
Acta2
Col1a1
Col1a2
Col3a1
Gapdh
Rpl32
Nfe2l2
Nqo1
Cyp1a
Nd1
Ppargc1a

ATGGGCTCCTTCTCCATCA
GGTGCTGTCCCAGATGATTC
TCTGAGGTGTGCCTGTGAAC
CTTTGCGGGTGTTGTAGGTT
GAGAGCATTTGGGGATGGTA
CGAACTCAAAGCAGGAGAGG
AACGCCAACTTCCTGGTGT
TGAGTGGCTGTCTTTTGACG
CCCAAAGTACCATGCAGAAAA
GAAGCCCATTTGAGGAGTCA
CCACCCGAGTTACCAATGAC
CCTGAAGAGCATCCGACACT
ACGCCATCAAGGTCTACTGC
GGAGAGAAGGGAACCAAAGG
CGTAAGCACTGGTGGACAGA
CATGGCCTTCCGTGTTCCTA
CTGGAGGTGCTGCTGATGT
CTGAACTCCTGGACGGGACTA
AGGATGGGAGGTACTCGAATC
AAGTGCAGATGCGGTCTTCT
TCCCCTACCAATACCACACC
AAGGTCCCCAGGCAGTAGAT

TCCAGGTGGTCTAGCAGGTT
GCCATTTCCTCCGACTTTTC
TGCTGCTGTCTTTGGTTGTC
AAAACTGGGAGGTTGTGCTG
GGCAACACTTTTCATTTTCCTC
CTGGGGGTTATTCACTCTGC
GGCTTCTTTCGCACAATCTC
CGTGGAGTTTGTTATCTTTGCT
ACGAAAAGATGCCTTGATGC
GATGTCTCTGCACACCCAGA
GACAGGCTTGGCGATTTTAG
CAGAGGCATAGAGGGACAGC
GAATCCATCGGTCATGCTCT
AGGGAAGCCAGTCATACCAG
CGGCTGGAAAGAAGTCTGAG
CCTGCTTCACCACCTTCTTGAT
GGGATTGGTGACTCTGATGG
CGGTGGGTCTCCGTAAATGG
TGCTAGAGATGACTCGGAAGG
AAAGTAGGAGGCAGGCACAA
GGCTCGTAAAGCTCCGAATA
TTTCGTGCTCATAGGCTTCA

difference for the mRNA expression level was calculated using 2−ΔΔCt.
2.6. Immunohistochemistry
After being blocked with 10% inactivated goat serum and 1% bovine serum albumin (BSA) in PBS, tissue sections were incubated
overnight at 4 °C with an anti-vimentin (1:200) and anti-4-HNE (1:100)
primary antibodies. Thereafter, sections were washed with 0.1% BSA in
PBS, blocked again with blocking buffer (30 min at room temperature),
and incubated with an Oregon green 488 anti-rabbit IgG (1:500) and
ATTO 647 N anti-mouse IgG (1:300) secondary antibodies to visualized
4-HNE and vimentin, respectively. Images were acquired using an
Olympus FV1000 confocal microscope with FluoView 1000 software
(Olympus, Center Valley, PA, USA).

2.4.2. Picrosirius red staining
Cardiac fibrosis was quantified on Picrosirius red (PSR)-stained
sections. Briefly, slides were washed and treated with phosphomolybdic
acid 0.2% aqueous. Sirius red was then added to the slides, followed by
addition of 0.1% in saturated picric acid and then 0.01 N hydrochloric
acid. Images were analyzed with Image Pro Premier 64-bit software
(Media Cybernetics, Rockville, MD, USA).
2.4.3. Masson's trichrome staining
Collagen quantification was performed on Masson's trichromestained sections according to manufacturer's instruction. Images were
analyzed with Image Pro Premier 64-bit software.

2.7. Protein isolation and expression analysis
Western blotting was performed to analyze the levels of fibrosisrelated protein expression, including TGF-β1, NOX4, total SMAD2 and
p-SMAD2, and 4-HNE-protein adducts in lysate of LV tissues. Briefly,
liquid nitrogen frozen ventricle tissues were homogenized with sonication in 300 μL RIPA buffer added with phosphatase inhibitor cocktail
(1:100). Tissue lysates were agitated gently at 4 °C for 1 h, followed by
centrifuge and supernatant collection. Protein concentration in the supernatants was determined by the BCA assay. Protein samples were
loaded onto Nupage 4–12% Bis-Tris gels. After electrophoresis, proteins
were electro-transferred to a PVDF membrane. The blotted membrane
was then blocked with TBS containing 5% fat-free milk powder and
0.1% Tween 20 for 1 h at room temperature and incubated with specific
primary antibodies overnight at 4 °C. The membrane was rinsed three
times and incubated with HRP-conjugated secondary antibodies (anti
rabbit or mouse depending on the primary antibody, 1:3000 for 1 h at
room temperature). Membrane was treated with Luminata Forte
Western HRP substrate (Millipore, Boston, MA) and then imaged with
MyECL imager (Thermo Fisher Scientific). Quantification analysis of
blots was performed with the ImageJ software. Targeted bands were
normalized to GAPDH.

2.4.4. TUNEL assay
Apoptotic cells were assessed using the DeadEnd Fluorometric
TUNEL System (Promega, Madison, WI) according to the manufacturer's instruction. Briefly, the slides were mounted with Permount
mounting medium, with the nuclei counterstained with DAPI. The
slides were then dried and imaged with a fluorescent microscope. Data
were analyzed with ImageJ software (NIH, Bethesda, MD, USA).
2.5. RNA isolation and transcript expression analysis
Total RNA was extracted and purified from the LV tissues with
RNeasy mini kit (Qiagen, Germantown, MD). cDNA was synthesized
from 500 ng of RNA using QuantiTect Reverse Transcription Kit
(Qiagen). Quantitative real-time PCR were performed using Select
Master Mix (Thermos Fisher Scientific, Asheville, NC) in a BioRad IQ5
detection system (BioRad, Portland, ME). Briefly, 25 μL PCR master mix
was prepared as follows: 5 ng cDNA template, 1× SYBR Select Master
Mix, and 300 nM gene-specific primers. The PCR amplification protocol
was the following: 5 min at 95 °C, 40 cycles at 95 °C for 15 s and 60 °C
for 45 s. Two reference genes were selected: Gapdh and Rpl32, both of
which showed constitutive expression across different groups. The expression levels of target genes were normalized to the average levels of
Gapdh and Rpl32. The specificity of PCR primers (Table 1) was confirmed with 1% agarose gel electrophoresis and melt curves. The fold

2.8. Mouse cardiac fibroblast isolation and in vitro experiments
Freshly isolated hearts from 9-week-old C57BL/6 male mice were
rinsed with HBSS. Left ventricles were gently separated and cut with a
3
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sterile scalpel into small pieces. Minced tissues were digested in collagenase II (600 IU) and DNase I (enzyme solution) in a petri dish. The
tissue was mechanically dissociated by pipetting up and down. The dish
was incubated at 37 °C for 15 min. After that, the supernatant was
collected into a 15 mL conical tube. The collagenase solution was added
to any remaining tissue fragments. The dissociation step was repeated
until a single cell suspension was obtained. After centrifugation and
rinsing, the resulting isolated cardiac fibroblasts (CF) were cultured in
DMEM/F12 medium supplemented with 15% FBS and 1% P/S antibiotics.
To study the role of MitoQ in ameliorating TGF-β1-induced profibrogenic signaling, CF cultures (within 3 passages) were starved in FBSfree DMEM medium for 24 h, followed by exposure to 10 ng/mL TGF-β
with or without the presence of MitoQ (300 nmol/L). After 24 h, cells
were harvested for transcript expression analysis and confocal imaging.
To further investigate the effect of MitoQ on pressure overload-induced TGF-β1 signaling activation, isolated CF were cultured on a thin
poly dimethylsiloxane (PDMS) membrane within custom cell culture
chambers. The cell culture chamber was then integrated within the
biomimetic cardiac tissue model (BCTM) platform and subjected to
cyclic stretch under different pressures as previously described [29].
While the inner wall of the ventricle experiences high pressure
(> 120 mmHg), the outer wall does not experience any pressure. Depending on the location of cells within the ventricular wall, the pressure
can range from ventricular pressure to 0 mmHg. Experimentally we
evaluated the equivalent pressure indicative of normal or pressure
overload conditions for cells cultured as a monolayer within the BCTM
and found that 15 mmHg and 30 mmHg correspond to normal and
pressure overload conditions, respectively. After 24 h of stretch in the
presence or absence of MitoQ, cells were collected for transcript expression analysis and confocal imaging.

[21,31]. In brief, the dish containing fluorescent dye-loaded CF was
equilibrated at 37 °C with unrestricted access to atmospheric oxygen on
the stage of an Olympus IX81 microscope. MitoSox images were recorded using an Olympus FV1000 confocal microscope with excitation
at 488 nm and analyzed offline with the ImageJ software.
2.11. Antibodies and chemicals
Primary antibodies against Vimentin (ab24525), 4-HNE (ab46545),
and NOX4 (ab133303) and HRP secondary antibodies were purchased
from AbCam (Cambridge, MA, USA). Antibodies against SMAD2 (mAb
#8685), p-SMAD2 (mAb # 8828), TGF-β1 (pAb #3711) were purchased from Cell Signaling Technology (Danvers, MA, USA). Secondary
antibody Oregon green 488, collagenase II, DMEM, FBS, and DNase I
were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
ATTO 647 N anti-mouse IgG were obtained from Sigma-Aldrich (St.
Louis, MO, USA). MitoSox and Alexa Fluor 488-conjugated wheat germ
agglutinin were purchased from Molecular Probes (Eugene, OR, USA).
All other chemicals are acquired from Sigma-Aldrich.
2.12. Statistical analysis
All data are reported as mean ± SEM. Statistical comparisons
among groups were performed using the two-way ANOVA Tukey's
multiple comparison test. P < 0.05 was considered statistically significant.
3. Results
3.1. AAC leads to rapid cardiac hypertrophic remodeling and heart failure
in mice

2.9. Mouse cardiomyocyte isolation and in vitro experiments

A new mouse HF model was developed by inducing a minimally
invasive ascending aortic constriction (AAC) with a calibrated titanium
clip. The rationale was that constriction of the ascending aorta, instead
of the transverse aorta, leads to a much higher hemodynamic load on
the heart, which causes accelerated development of cardiac hypertrophy and HF. Doppler echocardiography showed that the peak pressure gradient across the constriction was 4-fold higher in AAC mice as
compared with sham (99.5 ± 9.76 mmHg vs. 16.9 ± 5.2 mmHg), indicating that AAC induced much more severe pressure overload than
the commonly-performed transverse aortic constriction (TAC), which is
typically less than 2-fold [27,32]. Heart weight (HW), ventricular
weight, and HW normalized to tibia length were all significantly increased in AAC mice one week after surgery (Table 2). AAC mice also
exhibited a substantial increase in lung weight normalized to tibia
length (Table 2), consistent with pulmonary congestion. Furthermore,
AAC mice showed a significant decrease in body weight (Table 2).
Wheat germ agglutinin (WGA) staining was used to assess cardiomyocyte size (Fig. 1A), which showed that consistent with cardiac enlargement, average cardiomyocyte cross sectional areas in AAC mice

Adult mouse cardiomyocytes were isolated from 10-week-old male
C57BL/6 J mouse heart, as previously described [30]. After isolation,
cardiomyocytes were cultured in EMEM medium supplement with 10%
FBS, 2 mM ATP, 25 µM blebbistatin and 1% penicillin/streptomycin)
for 2 h in incubator (5% CO2, 37 °C). Then, the medium was changed to
EMEM medium with 0.1% BSA, 25 µM blebbistatin and 1% penicillin/
streptomycin, and cultures was maintained in the incubator for experiments. To further investigate the mechanism by which MitoQ regulates cardiac remodeling-associated lncRNA expression, cardiomyocytes were treated in the presence or absence of 10 μM phenylephrine
(PE) and 200 nM MitoQ for 24 h. Afterwards, cells were collected and
used for RNA isolation and lncRNA expression analysis.
2.10. Confocal imaging
ROS levels in CF cultures were measured with MitoSox (5 μmol/L),
an superoxide-sensitive fluorescent indicator, as described previously

Table 2
MitoQ improves cardiac hypertrophy induced by ascending aortic constriction (AAC) after one week of treatment.

Body Weight, g
Heart Weight, mg
LV Weight, mg
RV Weight, mg
Lung Weight, mg
TL, mm
Heart Weight/TL, mg/mm
Lung Weight/TL, mg/mm
Number of mice

Sham

Sham + MitoQ

AAC

AAC + MitoQ

24 ± 0.3
89.3 ± 0.8
72.5 ± 0.9
12.8 ± 0.6
146.9 ± 9.1
16.23 ± 0.11
5.50 ± 0.03
9.04 ± 0.52
6

24 ± 0.5
94.4 ± 5.9
75.3 ± 3.9
13.5 ± 0.7
147 ± 3.2
16.48 ± 0.09
5.72 ± 0.34
8.92 ± 0.24
4

21 ± 0.8 *
154.2 ± 2.9 *
130.8 ± 2.7 *
18.1 ± 1.5 *
296 ± 19.6 *
16.34 ± 0.06
9.43 ± 0.15 *
18.09 ± 1.16 *
6

22 ± 0.6
124.9 ± 7.8#
104.5 ± 6.3#
16.4 ± 1.3
168 ± 9.5#
16.30 ± 0.09
7.65 ± 0.46#
10.29 ± 0.57#
6

LV: left ventricle; RV: right ventricle; TL: tibia length. Values are means ± SEM. * : P < 0.05 vs. Sham. #: P < 0.05 vs. AAC.
4
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Fig. 1. MitoQ reduces pressure overload-induced cardiac hypertrophy in mice. A:
Representative images of WGA staining of LV
myocardium; B: quantification of WGA
staining (right); and C: Nppa and Nppb mRNA
expression levels; **: P < 0.01 vs. Sham. #:
P < 0.05 vs. AAC. ##: P < 0.01 vs. AAC.
n = 4–6 each group. Scale bars in A: 40 µm.
AAC: ascending aortic constriction; WGA:
wheat germ agglutinin.

(Table 2).
Importantly, echocardiography data showed that MitoQ treatment
significantly attenuated cardiac dysfunction in mice subjected to pressure overload (Fig. 2). Both LV fractional shortening and ejection
fraction were significantly higher in MitoQ-treated AAC mice than in
AAC (P < 0.05). MitoQ also effectively prevented pressure overloadinduced LV chamber remodeling. The end-systolic diameter and enddiastolic diameter, as well as end-diastolic volume (EDV) and end-systolic volume (ESV) in MitoQ-treated mice were essentially normalized
(Fig. 2 and Table 3). Furthermore, MitoQ treatment modestly improved
the reduced stroke volume in AAC mice (Table 3). As expected, MitoQ
did not affect LV function and chamber size in sham mice.

increased by 96% compared with sham (Fig. 1B). In addition, the
transcript levels of atrial natriuretic factor (Nppa) and brain natriuretic
peptide (Nppb), two cardiac hypertrophy marker genes, increased 36fold and 5-fold, respectively, in AAC mice (P < 0.001) (Fig. 1C).
AAC also caused rapid development of LV dysfunction and HF, as
shown by transthoracic echocardiography (Fig. 2A). In just one week,
LV fractional shortening (FS) and ejection fraction (EF) were reduced
70% (Fig. 2B) and 50%, respectively, in AAV mice as compared with
sham (Fig. 2C). In addition to a decline in LV function, AAC mice underwent substantial LV chamber remodeling. While there were no notable differences between the sham and AAC mice in LV interventricular septal and end-systolic posterior wall thickness, both endsystolic dimension (Fig. 2D) and volume (Table 3) markedly increased
after AAC (P < 0.01). In addition, end-diastolic dimension (Fig. 2E), as
well as end-diastolic posterior wall thickness, endo-diastolic volume,
and stroke volume were also altered in response to pressure overload
(Table 3).

3.3. MitoQ decreases cellular apoptosis and improves mitochondrial
biogenesis in AAC mouse myocardium
Loss of cardiomyocytes via apoptosis is known to contribute to
impaired cardiac function in response to pressure overload stress
[35–37]. Consistent with previous studies, in situ TUNEL assays showed
that cell death, reflected by the percentage of TUNEL positive nuclei,
was significantly higher in AAC mouse myocardium in comparison to
sham, which was greatly diminished by MitoQ (Fig. 3A and Fig. S1). In
addition, MitoQ decreased myocardial oxidative stress in response to
pressure overload, as detected by 4-hydroxynonenal (4-HNE) immunostaining (Fig. 3B) and western blotting (Fig. 3C). Finally, MitoQ
increased mitochondrial copy number and biogenesis in the AAC
myocardium, as measured by the ratio of mitochondrial DNA (ND1) to
nuclear DNA (CYP1a1) (Fig. 3D) and the levels of the gene Ppargc1a
which encodes the transcriptional coactivator PGC-1α (Fig. 3E), respectively.

3.2. MitoQ attenuates pressure overload-induced cardiac hypertrophy, LV
remodeling and HF
Previous studies have shown that MitoQ decreases ischemia-reperfusion-induced cardiac dysfunction [33] and cardiac hypertrophy
[34], we thus examined whether MitoQ imposes beneficial effects in
pressure overload mice. As reported in Table 2, both pathological heart
and lung enlargements in AAC mice were significantly mitigated by
MitoQ treatment. MitoQ also attenuated AAC-induced cardiomyocyte
hypertrophy measured by WGA staining and blunted upregulation of
the expressions of cardiac hypertrophic marker genes (Fig. 1). MitoQ
had no effect on HW, lung weight, and cardiomyocyte size in sham mice
5

Redox Biology 21 (2019) 101100

K.Y. Goh et al.

Fig. 2. MitoQ improves left ventricular (LV) contractility and chamber remodeling in AAC mice. The LV parameters were assessed using serial echocardiography one
week after surgery. A: Representative images showing M mode echocardiography of mice; B: Fractional shortening (FS); C: Ejection fraction (EF); D: End-systolic
diameter (ESD); and E: End-diastolic diameter (EDD). **: P < 0.01 vs. Sham. #: P < 0.05 vs. AAC. n = 4–6 each group. AAC: ascending aortic constriction.

3.4. MitoQ inhibits cardiac fibrosis in pressure overload-induced HF

pathological fibrogenesis in diseased hearts, suggesting that MitoQ
might affect this signaling pathway. Real time PCR revealed that there
were no significant differences in the levels of angiotensinogen (Agt)
and platelet-derived growth factor (Pdgf) mRNA expression among all
groups (Fig. 5A). However, the levels of expression of TGF-β1 and endothelin 1 (Edn1) transcripts were significantly upregulated in AAC
myocardium (Fig. 5A). The expression levels of TGF-β1 downstream
genes NADPH oxidase 4 (Nox4), connective tissue growth factor (Ctgf),
actin assembly-inducing protein 2 (Acta2), and collagens (Col1a1,
Col1a2, and Col3a1) were all upregulated in myocardium of AAC mice

Ventricular fibrosis is indicative of structural remodeling and typically accompanies cardiac dysfunction. To evaluate the degree of cardiac fibrosis and effect of MitoQ, Masson's trichrome and picrosirius red
(PSR) staining were performed on LV tissue sections. As shown in Fig. 4,
the fibrotic area increased dramatically (14–23 times) in AAC myocardium compared with sham and this was significantly attenuated by
MitoQ. Fibrosis development involves the transformation of fibroblasts
into active myofibroblasts, and TGF-β1 plays a major role in
6
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Table 3
MitoQ improves left ventricular chamber remodeling and contractile dysfunction induced by ascending aortic constriction (AAC) after one week of treatment.

Heart Rate, bpm
LV IVSd, mm
LV PWTd, mm
LV IVSs, mm
LV PWTs, mm
LV EDV, μL
LV ESV, μL
SV, μL
CO, μL
Number of mice

Sham

Sham + MitoQ

AAC

AAC+ MitoQ

456 ± 13.2
0.77 ± 0.06
0.65 ± 0.04
0.91 ± 0.07
0.95 ± 0.05
60.0 ± 0.97
23.2 ± 0.81
36.7 ± 0.81
16,698 ± 323
6

497 ± 10.2
0.70 ± 0.03
0.78 ± 0.03
0.94 ± 0.04
1.07 ± 0.04
56.7 ± 3.68
20.9 ± 1.85
35.8 ± 2.02
17,851 ± 1255
4

441 ± 16.4
0.87 ± 0.05
0.99 ± 0.07 *
0.92 ± 0.04
1.00 ± 0.07
73.6 ± 1.92 *
51.6 ± 2.77 *
21.9 ± 1.91 *
9673 ± 885 *
6

495 ± 13.3
0.82 ± 0.05
1.14 ± 0.06
0.92 ± 0.03
1.30 ± 0.07
56.6 ± 5.89 #
29.0 ± 4.23 #
27.6 ± 2.29
13,563 ± 975
6

LV: left ventricular; IVSd: interventricular septal end diastole; PWTd: diastolic posterior wall thickness; IVSs: interventricular septal end systole; PWTs: systolic
posterior wall thickness; EDV: end-diastolic volume; ESV: end-systolic volume; SV: stroke volume; CO: cardiac output. Values are means ± SEM. * : P < 0.05 vs.
Sham. #: P < 0.05 vs. AAC.

(Fig. 5B), indicating activation of the TGF-β1 signaling pathway in response to pressure overload. MitoQ treatment attenuated overexpression of TGF-β1 and all of its downstream genes in AAC mice
(Fig. 5B).
To confirm activation of the TGF-β signaling pathway and inhibitory effects of MitoQ on fibrogenesis in AAC mice at the protein
level, we measured TGF-β1, NOX4, p-SMAD2 and total SMAD2 protein

levels in LV tissue extracts by western blotting (Fig. 5C). Consistent
with the transcript data, AAC mice exhibited pronounced increases in
TGF-β1 and NOX4 protein levels (Fig. 5D). Phosphorylation of SMAD2
was also significantly increased in AAC mouse hearts, whereas the total
SMAD2 protein levels remained unchanged (Fig. 5D). With the exception of total SMAD2, MitoQ treatment in AAC mice, but not in sham
mice, diminished the overexpression of those proteins (Figs. 5C and

Fig. 3. Effect of MitoQ on cellular apoptosis, oxidative stress and mitochondrial biogenesis in pressure overload mouse hearts. A: Quantitative summary of TUNEL
assay. Please refer to Supplemental Fig. S1 for representative DAPI and TUNEL images; B: Representative immunostaining of 4-HNE and Vimentin in LV myocardium;
C: Representative western blotting of 4-HNE-protein adducts; D: Effect of MitoQ on mitochondrial copy number; and E: Effect of MitoQ on Ppargc1α mRNA expression. *: P < 0.05 vs. Sham. **: P < 0.01 vs. Sham. #: P < 0.05 vs. AAC. ##: P < 0.01 vs. AAC. n = 4–6 each group. 4-HNE: 4-hydroxynonenal; AAC:
ascending aortic constriction.
7
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Fig. 4. MitoQ attenuates cardiac fibrosis in AAC mice. A: Representative images of Masson trichrome staining. Please refer to Supplemental Fig. S2 for larger highquality images. B: Quantification of interstitial fibrosis measured by Masson trichrome staining; C: Representative images of Picrosirius red (PSR) staining; and D:
Quantification of interstitial fibrosis measured by PSR staining. **: P < 0.01 vs. Sham. #: P < 0.05 vs. AAC. ##: P < 0.01 vs. AAC. n = 4 each group. Scale bars:
200 µm. AAC: ascending aortic constriction.

5D).

overexpression of NOX4 and the downstream fibrotic genes and SMAD2
protein phosphorylation (Fig. 6A-D). To further understand the mechanism by which MitoQ regulates TGF-β1, we examined the effect of
MitoQ on the expression of nuclear factor (erythroid-derived 2) like 2
(Nrf2), a global antioxidant gene inducer, in CF exposed to TGF-β1.
Real-time PCR revealed that TGF-β1 caused significant downregulation
of Nrf2 and its downstream gene Nqo1 (that encodes NAD(P)H quinone
dehydrogenase 1), which were prevented by MitoQ (Fig. 6E). The
transcript expressions of Nrf2 and Nqo1 in control CF were not altered
by MitoQ (Fig. 6E). At the tissue level, MitoQ significantly increased
Nrf2 protein expression in AAC mice and slightly in sham mice
(Fig. 6F).

3.5. MitoQ prevents TGF-β-induced fibrosis in cardiac fibroblast cultures
To obtain more detailed information on the anti-fibrogenic role of
MitoQ in HF, we isolated and cultured cardiac fibroblasts (CF) from 9week-old C57BL/6J mice. These CF cultures were treated with TGF-β1
for 24 h in the presence or absence of MitoQ, followed by biochemical
analysis. Confocal imaging revealed that the fluorescent intensity of
MitoSox in TGF-β1-treated cultures was significantly higher than in
control (Fig. 6A), indicating that TGF-β1 induced mitochondrial superoxide production in CF. Associated with this finding, the expression
of Nox4, Ctfg, Acta2, and Col1a2 transcripts (Fig. 6B), as well as NOX4
and p-SMAD2 proteins (Fig. 6C and D), were upregulated in CF cultures
after TGF-β1 treatment, suggesting activation of fibrotic signaling.
Importantly, we found that TGF-β1 transcript expression increased
110% in TGF-β1-treated CF (Fig. 6B). MitoQ treatment abolished TGFβ1-induced oxidative stress and TGF-β1 upregulation and prevented

3.6. MitoQ inhibits TGF-β1 signaling in cardiac fibroblasts exposed to
pressure and mechanical stresses
Recently, the BCTM model has been developed that enables cultured
cells to be subjected to defined hemodynamic loads to mimic critical
8
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Fig. 5. MitoQ blunts activation of myocardial TGF-β1 and profibrogenic signaling in response to pressure overload. A: mRNA expression levels of Agt, Pdgf, TGF-β1
and Edn1; B: mRNA expression levels of Nox4, Ctgf, Acta2, and collagen (Col1a1, Col1a2 and Col3a1); C: Western blotting of TGF-β1, NOX4, phosphorylated SMAD2
(p-SMAD2), and total SMAD2; and D: Quantification of normalized TGF-β1 (left), NOX4 (middle) and p-SMAD2/total SMAD2 (right) protein expression. *: P < 0.05
vs. Sham. **: P < 0.01 vs. Sham. #: P < 0.05 vs. AAC. ##: P < 0.01 vs. AAC. n = 4–6 each group. Agt: angiotensinogen; Pdgf: platelet-derived growth factor; Edn1:
endothelin; Nox4: NADPH oxidase 4; Ctgf: connective tissue growth factor; Acta: actin assembly-inducing protein. AAC: ascending aortic constriction.

9
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Fig. 6. MitoQ attenuates NOX4-induced oxidative stress and SMAD2 signaling pathway in TGF-β-treated cardiac fibroblasts (CF). A: Representative confocal images
of MitoSox stained CF (left) and quantification of ROS measurement (right); B: mRNA expression of TGF-β1, Nox4, Ctgf, Acta2 and Col1a2 in CF; C: Representative
western blotting of NOX4, phosphorylated SMAD2 (p-SMAD2), and total SMAD2; D: Quantification of normalized NOX4 and p-SMAD2/total SMAD2 protein expression; E: mRNA expression of Nrf2 and Nqo1 in CF; and F: Nrf2 protein expression in AAC myocardium *: P < 0.05 vs. Control. #: P < 0.05 vs. TGF-β (A-E) or
AAC (F). n = 3 each group for CF (A-E) and n = 6 each group for mouse (F). NOX4: NADPH oxidase 4; Ctgf: connective tissue growth factor; Acta: actin assemblyinducing protein; Col1: collagen type I alpha 2 chain; Nrf2: nuclear factor erythroid 2-related factor 2; Nqo1: NAD(P)H quinone dehydrogenase 1. AAC: ascending
aortic constriction.

mechanical stresses experienced by cardiac cells in vivo [29]. Using the
BCTM, we examined the effect of MitoQ on CF cultures subjected to
pressure overload and mechanical stress that is similar to the in vivo
microenvironment in failing hearts. Confocal imaging of MitoSox
showed that 24-h pressure overload (i.e. 30 mmHg) and cyclic stretch
resulted in increased signal in CF cultures compared with static (i.e.
0 mmHg) and normal (i.e. 15 mmHg) pressure (Fig. 7A). The transcript
levels of TGF-β1 and the downstream fibrotic genes (e.g., Nox4, Ctgf,

and Col1a2) were moderately increased in CF exposed to normal
pressure as compared with the static conditions (Figs. 7B-E). Consistent
with the in vivo results, pressure overload resulted in a > 3-fold elevation in TGF-β1 expression (Fig. 7B). NOX4 transcript expression was
also upregulated in pressure overload CF (Fig. 7C), which may underlie
the increased ROS production. The activation of TGF-β1 signaling induced fibrosis in CF, which is indicated by increased Ctgf and Col1a2
transcript levels (Fig. 7D and E). MitoQ attenuated oxidative stress and
10
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Fig. 7. MitoQ attenuates oxidative stress and TGF-β1 signaling activation in cardiac fibroblasts (CF) expose to pressure overload (PO) and mechanical stretch. A:
Representative confocal images of MitoSox stained CF (left) and quantification of ROS measurement (right); B: mRNA expression of TGF-β1; C: mRNA expression of
Nox4; D: mRNA expression of Ctgf; and E: mRNA expression of collagen (Col1a2). *: P < 0.05 vs. Normal. #: P < 0.05 vs. PO. n = 3 each group. Nox4: NADPH
oxidase 4; Ctgf: connective tissue growth factor; Col1a2: collagen type I alpha 2 chain.

overexpression of TGF-β1, Nox4, Ctgf, and Col1a2 in CF cultures in response to pressure and mechanical stresses.

expression was significantly upregulated in myocardium of AAC mice
(Fig. 8A), which was consistent with the observations that AAC induced
accelerated cardiac hypertrophic remodeling in mice. The expression of
Malat-1, a lncRNA may regulate cardiac hypertrophy during hypoxiainduced pulmonary hypertension [38], was not significantly altered in
pressure overload mice (Fig. 8B), which is in agreement with a recent
study [39]. Expression of Mhrt, a cytoprotective lncRNA that is involved
in the regulation of oxidative stress-induced cellular apoptosis expression, decreased substantially in AAC mice (P < 0.01) (Fig. 8C). MitoQ
attenuated AAC-induced dysregulation of Chast and Mhrt and did not
influence their expression in sham mice.

3.7. MitoQ ameliorates dysregulation of cardiac remodeling-associated
lncRNA expression
Finally, we examined the effects of MitoQ on long noncoding RNAs
(lncRNAs) that have been reported to be associated with cardiac remodeling in HF, including cardiac hypertrophy-associated transcript
(Chast), metastasis associated in lung adenocarcinoma transcript 1
(Malat-1) and myosin heavy chain associated transcript (Mhrt). Chast
11
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Fig. 8. MitoQ ameliorates dysregulation of cardiac remodeling-associated lncRNAs. A-C: Effect of MitoQ on lncRNA Chast (A), Malat-1 (B), and Mhrt (C) expression in
mouse myocardium; D-F: Effect of MitoQ on the expression of Chast (D) in TGF-β-treated CF, and Malat-1 (E) and Mhrt (F) in phenylephrine (PE)-treated mouse CM.
Chast: cardiac hypertrophy-associated transcript; Malat-1: metastasis associated in lung adenocarcinoma transcript 1; and Mhrt: myosin heavy chain associated RNA
transcript. *: P < 0.05 vs. Sham (in A-C) or Control (D and F); #: P < 0.05 vs. AAC (A-C) or TGF-β (D) or PE (F). n = 6 each group for A-C and n = 3 each group for
D-F.

We next tested the regulatory effect of MitoQ on these lncRNAs in
isolated cardiac myocytes (CM) and CF subjected to PE (phenylephrine)
and TGF-β1 treatment, respectively. Twenty-four hours TGF-β1 treatment caused significant upregulation of Chast which was prevented by
MitoQ (Fig. 8D). The expressions of Malat-1 were not changed by either

PE or MitoQ (Fig. 8E), but Mhrt decreased significantly in PE-treated
CMs, and the downregulation was blocked by MitoQ (Fig. 8F). Interestingly, real-time PCR showed that the expression of those cardiac
remodeling-associated lncRNAs are cell type specific: Chast expression
was barely detected in CM while Mhrt expression was very low in CF
12
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we developed a new minimally invasive ascending aortic constriction
(AAC) mouse model that exhibits rapid and robust development of
cardiac dysfunction and HF. In particular, both HW and lung weight
doubled, and FS and EF dropped more than 65% in AAC mice in as short
as one week. These characteristics make our model more (patho)physiologically relevant to human HF for assessing the therapeutic impact
of MitoQ on pressure overload-dependent cardiac dysfunction compared to the traditional TAC models. Given those advantages, it is worth
mentioning that the etiology and pathogenesis of AAC-induced HF is
not exactly the same as that in human HF, which is a progressive
multifactorial disease that may take years to develop. In addition,
human HF represents the summation of multiple anatomic, functional,
electrical and metabolic alterations which may induce some secondary
complications. These limitations should be taken into account when
considering the path towards translational application of these findings.
Using the AAC model, we demonstrate that MitoQ protects against
pressure overload-induced cardiac remodeling and LV dysfunction in
mice, as assessed by echocardiographic measurement of LV dimensions,
chamber size, and contractility. Pathological changes, including organ
weights, cellular sizes, and fibrosis are also ameliorated by MitoQ. The
different therapeutic role of MitoQ in HF between the present AAC and
the previous TAC [22] studies could due to several important factors
most notably the dosing regimen and animal model. We elected to
administer MitoQ by oral gavage, rather than drinking water since in
initial studies we noted that the mice (both AAC and sham) consumed
significantly less water over time (~3.2 mL/day/mouse without MitoQ
vs. ~0.5 mL/day/mouse with MitoQ), decreasing the effective MitoQ
dose. Secondly, we began to feed mice with MitoQ 24 h after AAC
surgery, while in the TAC rat study MitoQ was given three days after
the surgery [22]. As ROS levels and dysregulation of redox signaling
may arise within a few days after aortic constriction, allowing animals
to receive timely MitoQ treatment might be critical. Another important
aspect is that AAC, rather than TAC, was used in this study to induce
pressure overload. As discussed above, AAC caused a rapid and severe
LV remodeling leading to HF in mice. In particular, we observed severe
cardiac fibrosis in AAC mice, a key factor underlying LV remodeling
and reduced contractility, and MitoQ effectively ameliorated cardiac
fibrosis. However, it was not discussed whether cardiac fibrosis occurred in the TAC rat study. Finally, the dosage of MitoQ used in the
present study was higher than that used in the TAC rat study (100 μM in
drinking water). Altogether, it appears that the dosing regimen and
timing of MitoQ treatment and types of animal and disease model may
all contribute to the greater efficacy of MitoQ on LV dysfunction in HF
observed in the present study.
Cardiac fibrosis is a late-stage irreversible process during the progression of HF, which greatly increases the stiffness of the heart wall
and reduces the contractility and compliance of cardiac muscle. Fibrosis
can be activated by multiple sources, including increased mechanical
stretch [45], dysregulated redox signaling [41], paracrine cytokines
from injured cells [46], and infiltration of circulatory immune cells
[28]. Secreted cytokines from fibroblasts and cardiomyocytes, including TGF-β1, endothelin, angiotensinogen, and connective tissue
growth factor, activate differentiation of fibroblast into myofibroblast
and extracellular matrix remodeling. Of those growth factors, we found
that TGF-β1 transcript expression in AAC myocardium nearly doubled
when compared with sham. SMAD2 phosphorylation and expression of
downstream genes were also upregulated, indicating activation of the
canonical fibrotic pathway. In addition, our data clearly show that TGFβ1 contribute to redox signaling through NOX4, in accordance with
previous studies [10]. Importantly, NOX4 modulates mitochondrial
ROS production [11,47], which together enhance TGF-β1 expression,
resulting in further ROS production through a positive-feedback mechanism. Thus, TGF-β1-activated ROS production can amplify the TGFβ1-mediated fibrogenic signaling, as suggested previously [48]. We
speculate that MitoQ attenuates AAC-induced cardiac fibrosis by suppressing the redox-dependent retrograde signaling. The effects of MitoQ

Fig. 9. Summary of the novel insights of the current study beyond past research
on MitoQ and heart failure. Using the AAC-induced pressure overload mouse
model we demonstrate that MitoQ is capable of reducing fibrosis and LV contractile dysfunction in HF by suppressing the profibrotic TGF-β1-NOX4-ROS
vicious cycle and dysregulation of the cardiac remodeling-associated lncRNAs.

(cycle threshold values were 31–33 compared with ~17 for GAPDH).
4. Discussion
The main results of the present study, as summarized in Fig. 9, are
that (1) ascending aortic constriction induces rapid development of
cardiac hypertrophic remodeling and HF in mice; (2) MitoQ improves
pressure overload-induced cardiac hypertrophic remodeling and LV
contractile dysfunction; (3) MitoQ suppresses the TGF-β1, NOX4 and
ROS positive feedback loop, leading to reduced fibrosis; and (4) MitoQ
regulates expression of lncRNAs involving in cardiac remodeling. These
new findings support the notion that the TGF-β1-NOX4-ROS signaling
axis is critical for modulation of cardiac hypertrophy and fibrosis in the
context of pressure overload-induced HF.
Over the last few decades various animal models have been developed to explore the pathophysiology and treatment of cardiac hypertrophy and HF. While large animal models such as swine and canine are
considered more clinically relevant, small animals, especially mouse,
are increasingly used for mechanistic studies in HF, largely due to recent technical advances in gene editing and manipulation [40]. Currently-used mouse models of cardiac hypertrophy and HF are typically
generated by genetic manipulation such as Gαq overexpression [41]
and CaMKII overexpression [42], or surgical introduction such as aortic
constriction [43] and left coronary ligation [44]. In the current study
13
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on TGF-β1 and NOX4 expression and redox signaling are confirmed in
two in vitro experiments in which isolated CF were exposed to TGF-β1
treatment or pressure overload, respectively. The direct anti-fibrosis
effect of MitoQ has been reported in liver [19,49], kidney [20], and
lung [50]. The present study demonstrates that MitoQ can also retard
fibrosis in hearts subjected to pressure overload. Intriguingly, we
showed that TGF-β1 treatment suppressed Nrf2 and Nqo1 mRNA expression in isolated CF (Fig. 6E). While this appears potentially counterintuitive but would suggest that it is a key characteristic of the pathology of HF. For example, Xing et al. reported that expressions of
cytosolic and nuclear Nrf2 proteins are reduced in myocardium of mice
subjected to TAC surgery [51]. In non-cardiac tissue, it has been shown
that increased TGF-β inhibits Nrf2 expression and its ability for antioxidants production in lung fibroblast, thereby leads to oxidative stress
[52]. These changes may create a feed forward cycle which amplifies
and increases TGF-β expression. Importantly, MitoQ increased Nrf2
expression in both the AAC myocardium and TGF-β1-treated CF, suggesting that MitoQ ameliorates TGF-β1 signaling and fibrosis likely by
activating the Nrf2 signaling that suppresses the TGF-β1-NOX4-ROS
redox signaling axis.
Emerging evidence show that long noncoding RNAs (lncRNAs) play
prominent regulatory roles in the development of cardiovascular diseases (see recent reviews [25,53–55]). One of the most recently identified lncRNAs associated with cardiac hypertrophic remodeling in HF
is Chast. It has been shown that myocardial Chast expression is upregulated in pressure overload mice and aortic stenosis patients [56].
Similarly, we found that the Chast expression levels were significantly
higher in AAC mice than in sham, accompanied by substantial cardiac
hypertrophy. Another lncRNA we have examined is Mhrt that confers
cytoprotective effects [57]. The target of Mhrt is Brg1, a stress-activated
chromatin-remodeling factor that induces aberrant gene expression and
cardiac myopathy [58]. Consistent with a recent study showing that
Mhrt was downregulated in cardiac pressure overload [57], we found
that myocardial Mhrt expression reduced 70% in AAC mice as compared with sham. The detailed mechanism underpinning the regulation
of lncRNAs in failing hearts is poorly understood. It has been reported
that lncRNAs respond to environmental and developmental conditions
similarly with protein-coding genes [59,60]. In addition, several studies
showed that the promoters of lncRNAs are almost as conserved as those
of protein-coding genes [61,62]. Moreover, the transcription and processing of most lncRNAs appears to be similar to those of protein-coding
genes. Altogether, we conjecture that the canonical TGF-β1-NOX4-ROS
signaling, which is markedly activated in the AAC heart, is involved in
the dysregulation of Chast and Mhrt expression, as suggested by our
data (Fig. 8D) and several recent studies [63–65]. Intriguingly, we
showed that MitoQ significantly diminished the dysregulation of those
lncRNA expression in pressure overload hearts and PE/TGF-β treated
CM/CF, supporting the potential role of TGF-β-NOX4-ROS redox signaling axis in lncRNA regulation. With that being said, future mechanistic studies are warranted to completely understand how MitoQ is
involved in the regulation of lncRNAs. Importantly, our finding of cell
type-specific expression of those lncRNAs may lead to novel targeted
treatment of HF patients.
In summary, the current study provides direct evidence that the
mitochondrial-targeted redox modulatory compound, MitoQ, attenuates cardiac remodeling and improves LV contractile dysfunction in
pressure overload-induced HF in mice. The mechanism, at least in part,
involves inhibition of interplay between TGF-β1 and mitochondrialassociated redox signaling, which ameliorates the dysregulation of
profibrogenic genes, antioxidant gene inducer Nrf2, and cardiac remodeling-associated lncRNAs. It has to be noted that HF is a multifactorial syndrome, and we cannot exclude the protective effect of
MitoQ on other subcellular systems that can also contribute to the
improved pressure overload-induced cardiac dysfunction.
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